COBRE/CCII researcher, Dr. Kavitha Yaddanapudi obtained Research Project Grant (R01) from the National Institute of Health with a high-priority score of the top 2% percentile. Dr. Kavitha Yaddanapudi became the first graduate of the COBRE/CCII program - as a major accomplishment in line with COBRE/CCII's goal to support the research and career development of junior investigators in the thematic area.


  • Morrissey S, Geller A, Hu X, Tieri D, Ding C, Klaes C, Cooke E, Woeste M, MartinZ, Chen O, Bush S, Zhang H, Cavallazzi R, Clifford S, Chen J, Ghare S, Barve S, Cai L, Kong M, Rouchka E, McLeish K, Uriarte S, Watson C, Huang J, Yan J. 2021. A Specific Low-Denisty Neutrophil Population Correlates with Hypercoagulation and Disease Severity in Hospitalized COVID-19 Patients. JCI insight . 6(9):e148435.
  • Huxol H, Yaddanapudi K, Bushau-Sprinkle A, Palmer K, Bickel S, Morton R, Harris C (2022). COVID-19 Disease in Children with Medical Complexity in a Pediatric Long-term Care Facility: A Case Series. Pediatr Infect Dis J. 2022 Sep 1;41(9):e403-e405. doi: 10.1097/INF.0000000000003587. Epub 2022 May 27. PubMed PMID: 35622420; PubMed Central PMCID: PMC9359677.
  • Li, Q., Goggin, K. E., Seo, S., Warawa, J. M., & Egilmez, N. K. (2022). Anti-PD-1 antibody-activated Th17 cells subvert re-invigoration of antitumor cytotoxic T-lymphocytes via myeloid cell-derived COX-2/PGE2. Cancer immunology, immunotherapy : CII, 10.1007/s00262-022-03285-3. Advance online publication.
  • Sarkar OS, Donninger H, Al-Rayyan N, Chew LC, Stamp B, Zhang X, Whitt A, Li C, Hall M, Mitchell RA, Zippelius A, Eaton JW, Chesney JA, Yaddanapudi K (2022). Tumor-educated monocytes suppress T cells via adenosine and depletion of adenosine in the tumor microenvironment with adenosine deaminase enzyme promotes response to immunotherapy. bioRxiv doi: 
  • Yaddanapudi K, Stamp BF, Subrahmanyam PB, Smolenkov A, Waigel SJ, Gosain R, Egger ME, Martin RCG, Buscaglia R, Maecker HT, McMasters KM, Chesney JA (2022) Single‐Cell Immune Mapping of Melanoma Sentinel Lymph Nodes Reveals an Actionable Immunotolerant Microenvironment. Clin. Cancer Res. May 13;28(10):2069-2081. PMID: 35046061. Accompanying commentary in Clin. Cancer Res. PMID: 35262676.